+ 0.35
+ 0.09%
+ 1071.44
+ 2.5%
+ 0.36
+ 0.1%
+ 0.78
+ 0.18%

Why Moderna Shares Dipped On Tuesday

July 27, 2021 2:45 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Moderna (NASDAQ:MRNA) shares are trading lower on reports suggesting the company is having supply issues.

According to a Reuters report, the company said that it does not have a sufficient stock of vaccines in storage to smooth shortfalls or delays and said the current delay can lead to short-term adjusting in the coming 2-4 weeks. 

Moderna is a biotechnology company that develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. As of March 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities. 

At the time of publication, shares of Moderna were trading 2.9% at lower at $326.29. The stock has a 52-week low of $54.21 and a 52-week high of $362. 

See also: How to Buy Moderna (NASDAQ:MRNA) Stock 

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Movers Trading Ideas

Related Articles

Moderna Shares See Volume Spike As Shares Mark New Session Low Below $430 Level, Stock Down ~6% For Session

Moderna And Nvidia Lead The Nasdaq-100

U.S. indices were trading higher and continued to gain as investors weigh Wednesday's Fed decision to keep rates unchanged. Markets also rebounded following recent weakness driven by China volatility. read more

Moderna Shares Break Above $442 Level, Now Up ~2% For Session

Moderna Shares Now Over $440 Level, Up 1.5%